Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

References

• CarmeliYEliopoulosGMozaffariESamoreMHealth and economic outcomes of vancomycin-resistant enterococciArch Intern Med2002162192223222812390066
   PubMedGoogle Scholar
• CosgroveSESakoulasGPerencevichENSchwaberMJKarchmerAWCarmeliYComparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysisClin Infect Dis2003361535912491202
   PubMed Web of Science ®Google Scholar
• HidayatLKHsuDIQuistRShrinerKAWong-BeringerAHigh-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicityArch Intern Med2006166192138214417060545
   PubMedGoogle Scholar
• BoucherHWTalbotGHBradleyJSBad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaClin Infect Dis200948111219035777
   PubMed Web of Science ®Google Scholar
• GiskeCGGeJNordmannPActivity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosaJ Antimicrob Chemother200964243043119474066
   PubMed Web of Science ®Google Scholar
• RiceLBFederal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPEJ Infect Dis200819781079108118419525
   PubMed Web of Science ®Google Scholar
• KlevensRMEdwardsJRRichardsCLJrEstimating health care-associated infections and deaths in US hospitals, 2002Public Health Rep2007122216016617357358
   PubMed Web of Science ®Google Scholar
• GaynesREdwardsJROverview of nosocomial infections caused by gram-negative bacilliClin Infect Dis200541684885416107985
   PubMed Web of Science ®Google Scholar
• TalbotGHBradleyJEdwardsJEJrGilbertDScheldMBartlettJGBad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClin Infect Dis200642565766816447111
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionGram-negative bacteria infections in healthcare settings2011 Available from: http://www.cdc.gov/hai/organisms/gram-negative-bacteria.htmlAccessed April 29, 2013
   Google Scholar
• SteinGEAntimicrobial resistance in the hospital setting: impact, trends, and infection control measuresPharmacotherapy20052510 Pt 244S54S16178675
   PubMed Web of Science ®Google Scholar
• MauldinPDSalgadoCDHansenISDurupDTBossoJAAttributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteriaAntimicrob Agents Chemother201054110911519841152
   PubMed Web of Science ®Google Scholar
• AgnelloMWong-BeringerADifferentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosaPloS One201278e4297322905192
   PubMed Web of Science ®Google Scholar
• CossonPZulianelloLJoin-LambertOPseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host systemJ Bacteriol2002184113027303312003944
   PubMed Web of Science ®Google Scholar
• ShaverCMHauserARRelative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lungInfect Immun200472126969697715557619
   PubMed Web of Science ®Google Scholar
• Van DeldenCIglewskiBHCell-to-cell signaling and Pseudomonas aeruginosa infectionsEmerg Infect Dis1998445515609866731
   PubMed Web of Science ®Google Scholar
• VeesenmeyerJLHauserARLisboaTRelloJPseudomonas aeruginosa virulence and therapy: evolving translational strategiesCrit Care Med20093751777178619325463
   PubMed Web of Science ®Google Scholar
• GiamarellouHAntoniadouAAntipseudomonal antibioticsMed Clin North Am2001851194211190351
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance SystemNational Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004Am J Infect Control200432847048515573054
   PubMed Web of Science ®Google Scholar
• SievertDMRicksPEdwardsJRAntimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010Infect Control Hosp Epidemiol201334111423221186
   PubMed Web of Science ®Google Scholar
• LivermoreDMMultiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin Infect Dis31200234563464011823954
   PubMed Web of Science ®Google Scholar
• RossoliniGMMantengoliETreatment and control of severe infections caused by multiresistant Pseudomonas aeruginosaClin Microbiol Infect200511Suppl 4173215953020
   PubMed Web of Science ®Google Scholar
• KallenAJHidronAIPatelJSrinivasanAMultidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008Infect Control Hosp Epidemiol201031552853120334552
   PubMed Web of Science ®Google Scholar
• AloushVNavon-VeneziaSSeigman-IgraYCabiliSCarmeliYMultidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impactAntimicrob Agents Chemother2006501434816377665
   PubMed Web of Science ®Google Scholar
• CaoBWangHSunHZhuYChenMRisk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infectionsJ Hosp Infect200457211211815183240
   PubMed Web of Science ®Google Scholar
• LivermoreDMMushtaqSGeYChequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing EnterobacteriaceaeJ Antimicrob Chemother20106591972197420595207
   PubMed Web of Science ®Google Scholar
• TakedaSNakaiTWakaiYIkedaFHatanoKIn vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosaAntimicrob Agents Chemother200751382683017145788
   PubMed Web of Science ®Google Scholar
• TakedaSIshiiYHatanoKTatedaKYamaguchiKStability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosaInt J Antimicrob Agents200730544344517644319
   PubMed Web of Science ®Google Scholar
• SaderHSFlammRKStreitJMJonesRNActivity of novel antimicrobial ceftolozane/tazobactam tested against contemporary clinical strains from USA hospitals (2011)Abstracts: 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2012
   Google Scholar
• TodaAOhkiHYamanakaTSynthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205Bioorg Med Chem Lett200818174849485218701284
   PubMed Web of Science ®Google Scholar
• Cubist PharmaceuticalsCeftolozane/tazobactam – overview Available from: http://www.cubist.com/sup/img/drugs/Ceft-Taz-overview_880.pngAccessed January 10, 2013
   Google Scholar
• Cubist PharmaceuticalsGram-negative: ceftolozane/tazobactam Available from: http://www.cubist.com/products/cxa_201Accessed January 10, 2013
   Google Scholar
• MoyáBZamoranoLJuanCGeYOliverAAffinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosaAntimicrob Agents Chemother20105493933393720547785
   PubMed Web of Science ®Google Scholar
• ShlaesDMNew β-lactam-β-lactamase inhibitor combinations in clinical developmentAnn N Y Acad Sci2013127710511423346860
   PubMed Web of Science ®Google Scholar
• MushtaqSWarnerMLivermoreDMActivity of cephalosporin CXA-101 (FR264205) with β-lactamase inhibitors vs EnterobacteriaceaeAbstracts: 48th Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2009
   Google Scholar
• LivermoreDMMushtaqSGeYWarnerMActivity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesInt J Antimicrob Agents200934540240619428220
   PubMed Web of Science ®Google Scholar
• MoyaBZamoranoLJuanCPérezJLGeYOliverAActivity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patientsAntimicrob Agents Chemother20105431213121720086158
   PubMed Web of Science ®Google Scholar
• ZamoranoLJuanCFernández-OlmosAGeYCantónROliverAActivity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patientsClin Microbiol Infect20101691482148720002107
   PubMed Web of Science ®Google Scholar
• SaderHFarrellDJonesRNActivity of the novel antimicrobial CXA-201 tested against contemporary clinical strains from European hospitals (2012)Presented at: 22nd Annual Meeting of the European Congress of Clinical Microbiology (ECCMID)March 31–April 3, 2012London, UK
   Google Scholar
• MillerBHershbergerEBenzigerDTrinhMFriedlandIPharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending dosesAntimicrob Agents Chemother20125663086309122450972
   PubMed Web of Science ®Google Scholar
• MillerBChandorkarGUmehOSafety and PK of IV ceftolozane/tazobactam 3 g Q8h and cumulative fraction of response in plasma and epithelial lining fluid in a simulated VAP populationAbstracts: 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2012
   Google Scholar
• GeYWhitehouseMJFriedlandITalbotGHPharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusionsAntimicrob Agents Chemother20105483427343120457817
   PubMed Web of Science ®Google Scholar
• MillerBHershbergerEBenzigerDPharmacokinetics of CXA-101/tazobactam in subjects with mild or moderate renal impairmentPresented at: 21st Annual Meeting of the European Congress of Clinical MicrobiologyMay 7–10, 2011Milan, Italy
   Google Scholar
• ChandorkarGHuntingtonJAGotfriedMHRodvoldKAUmehOIntrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjectsJ Antimicrob Chemother201267102463246922773741
   PubMed Web of Science ®Google Scholar
• SoonRLForrestAHoldenPNIn vitro pharmacodynamics of ceftolozane/tazobactam against β-lactamase producing Escherichia coliAbstracts: 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2012
   Google Scholar
• CraigWAAndesDRIn vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic miceAntimicrob Agents Chemother20135741577158223274659
   PubMed Web of Science ®Google Scholar
• VanscoyBMendesRENicasioAMPharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection modelAntimicrob Agents Chemother20135762809281423629705
   PubMed Web of Science ®Google Scholar
• HershbergerEMouksassiMSteenbergenJNCXA-101/tazobactam probability of target attainment using population pharmacokinetic analysisPresented at: 21st European Congress of Clinical Microbiology and Infectious Diseases and Twenty-seventh International Congress of ChemotherapyMay 7–10, 2011Milan, Italy
   Google Scholar
• CabotGMuletXMoyaBDynamics and mechanisms of resistance development to ceftazidime, meropenem and ceftolozane/tazobactam in wild-type and mutator P. aeruginosa strainsAbstracts: 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2012
   Google Scholar
• ClinicalTrials.gov [website on the Internet]Safety and efficacy of IV CXA-101 and IV ceftazidime in patients with complicated urinary tract infections2010 Available from: http://clinicaltrials.gov/ct2/show/NCT0921024?term=CXA±and±ceftazidime&rank=1Accessed June 7, 2013
   Google Scholar
• UmehOCebrikDFriedlandIA double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infection (cUTI)Abstracts: 50th Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2010
   Google Scholar
• ClinicalTrials.gov [website on the Internet]Study of intravenous ceftolozane/tazobactam vs piperacillin/tazobactam in ventilator associated pneumonia2013 Available from: http://clinicaltrials.gov/ct2/show/NCT1853982?term=ceftolozane&rank=2Accessed May 17, 2013
   Google Scholar
• JacquelineCBretonniereCDesessardCIn vivo activity of CXA-101 against Pseudomonas aeruginosa(PA) in a rabbit experimental model of pneumonia: comparison with ceftazidime (CAZ), piperacillin/tazobactam (TZP), and imipenem (IMP)Abstracts: 51st Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2011
   Google Scholar
• HsuDIOkamotoMPMurthyRWong-BeringerAFluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomesJ Antimicrob Chemother200555453554115728150
   PubMed Web of Science ®Google Scholar
• NguyenLHHsuDIGanapathyVShrinerKWong-BeringerAReducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcomeJ Antimicrob Chemother200861371472018222951
   PubMed Web of Science ®Google Scholar